The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
Bloomberg
Thermo Fisher Scientific Inc. agreed to buy Dutch drug-ingredients maker Patheon NV for $5.2 billion, extending the acquisition binge that helped turn it into one of the world’s biggest manufacturers of diagnostic and testing equipment.
Thermo Fisher will pay $35 a share in cash, 35 percent above Patheon’s closing price, before Bloomberg News reported that the companies were in talks. Including debt, the purchase value comes to about $7.2 billion, Thermo Fisher said in a statement on Monday.
The deal adds to the $22 billion in acquisitions announced by Thermo Fisher over the past five years, according to data compiled by Bloomberg. Last year, the Waltham, Massachusetts-based company beefed up its suite of testing and technology services by buying electron microscope maker FEI Co. for more than $4 billion. It now offers equipment, instruments and supplies to laboratories and medical research facilities and is a major player in technology used to sequence the human genome.
Through Friday, Patheon’s shares had risen 24 percent since they were sold in an initial public offering in July at $21 each on the New York Stock Exchange.